UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for 2025, is a de-risked story from a fundamental perspective with an accelerating brand transition, the analyst tells investors in a research note. The firm expects Teva to announce the sale of the Active Pharmaceutical Ingredients unit with Q4 results next week, and is now modeling Austedo 2027 sales at $2.4B, with Uzedy 2030 sales at $529M.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- FDA adds boxed warning to Teva’s Copaxone for allergic reaction
- Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
- Teva price target raised to $30 from $23 at Piper Sandler
- Teva call volume above normal and directionally bullish
- Teva enters pact with Klinge Biopharma, Formycon to commercialize FYB203